Brain atrophy reduced with fingolimod


REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – An analysis of three phase III studies reports a significant reduction in the rate of brain atrophy during treatment with fingolimod (Cohen et al. AAN 2013; abstract S51.006). Brain volume was measured using SIENA/SIENAX. Data were analysed for the two-year placebo-controlled FREEDOMS and FREEDOMS II trials, and the one-year TRANSFORMS trial comparing fingolimod to interferon-beta-1a IM.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page